ATAI Life Sciences is a venture capital fund investing in companies developing advanced treatments for mental health disorders. They focus on early-stage pharma and biotech businesses, providing support during the Series B funding stage. Their goal is to create effective mental health treatments by leveraging expertise and resources across their portfolio. One of their notable investments is Beckley Psytech. ATAI Life Sciences aims to address unmet mental health needs, enabling everyone to lead a more fulfilling life.
